Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2326 - 2350 of 15090 in total

Suvorexant

Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Approved
Investigational
Matched Description: … wakefulness and arousal. ... Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing …
Matched Categories: … Hypnotics and Sedatives ... Miscellaneous Anxiolytics Sedatives and Hypnotics …

Capromab pendetide

Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide Indium In-111 during imaging to evaluate...
Approved
Matched Description: … specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and …
Matched Categories: … Indicators and Reagents ... Amino Acids, Peptides, and Proteins …

Ancrod

Ancrod, marketed as Viprinex, is a defibrinogenating agent derived from Malayan pit viper venom. The defribrinogenation of blood results in an anticoagulant effect. Currently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S....
Approved
Investigational
Matched Description: … ischemic stroke, a life threatening condition caused by the blockage of blood vessels supplying blood and …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs …

Hydrocortisone succinate

Approved
Matched Iupac: … 3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}-4-oxobutanoic acid …
Matched Categories: … Hydrocortisone and derivatives ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Colestilan chloride

Colestilan is an ingredient in the EMA-withdrawn product BindRen.
Approved
Investigational
Withdrawn
Matched Categories: … Drugs for Treatment of Hyperkalemia and Hyperphosphatemia …

Cemiplimab

Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses. Cemiplimab was first approved by the FDA on September 28, 2018, as the first FDA-approved treatment...
Approved
Investigational
Matched Description: … [A39201,A254177,L4615] It was later approved to be used in basal cell carcinoma and non-small non-small …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Spiramycin

Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium. Spiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in...
Approved
Matched Description: … Toxoplasma gondii and Cryptosporidium. ... Resistant organisms include Enterobacteria, pseudomonads, and moulds. ... a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and …
Matched Categories: … spiramycin and metronidazole ... Macrolides, Lincosamides and Streptogramins …

Normethadone

Normethadone is used as an opioid antitussive in combination with DB11610. It is marketed in Canada by Valeant under the tradename Cophylac.
Approved
Illicit
Matched Categories: … Cough and Cold Preparations ... Opium Alkaloids and Derivatives …

Activated charcoal

Activated charcoal, or activated carbon, is an amorphous form of carbon prepared from incomplete combustion of carbonaceous organic matter. It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high...
Approved
Matched Description: … oral ingestion of certain medications or poisons by absorbing most drugs and toxins. ... It is used as a gastric decontaminant and emergency medication to treat poisonings following excessive ... passed over its surface to make a fine network of pores, producing a material with large surface area and …
Matched Categories: … Antacids and Adsorbents ... Alimentary Tract and Metabolism …

Sodium aurotiosulfate

Approved
Experimental
Matched Categories: … Antiinflammatory and Antirheumatic Products …

Anthrax immune globulin human

Anthrax immune globulin is a human antibody given with antibiotics for the treatment of anthrax. It is derived from the plasma of humans immunized with BioThrax (adsorbed anthrax vaccine), which is then further purified. Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing...
Approved
Matched Description: … polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and ... to have direct antibacterial activity against anthrax bacteria, which otherwise may continue to grow and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Garlic

Garlic allergenic extract is used in allergenic testing.
Approved
Nutraceutical
Matched Categories: … Herbs and Natural Products …

Papaya

Papaya allergenic extract is used in allergenic testing.
Approved
Matched Categories: … Herbs and Natural Products …

Diphemanil

Approved
Vet approved
Withdrawn
Matched Categories: … Alimentary Tract and Metabolism ... diphemanil and psycholeptics …

Danicopan

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction.[A263501,L50417] Both hemolysis and thrombophilia are mediated primarily by the complement system. Standard therapy for PNH involves the use of complement C5 inhibitors (e.g. eculizumab, ravulizumab) which are effective in mitigating complement-mediated intravascular...
Approved
Investigational
Matched Description: … [A263501,L50417] Both hemolysis and thrombophilia are mediated primarily by the complement system. ... hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and ... Japan for patients with PNH,[A263506,L50416] shortly after which the EMA adopted a positive opinion and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Potassium aspartate

Approved
Experimental
Matched Categories: … Amino Acids, Peptides, and Proteins …

Besilesomab

Besilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis [FDA Label]. Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like...
Approved
Matched Description: … Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and ... various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the Netherlands, and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

L-arginine

Approved
Nutraceutical
Matched Categories: … Amino Acids, Peptides, and Proteins …

Belatacept

Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it...
Approved
Investigational
Matched Description: … domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and ... Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Axicabtagene ciloleucel

Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. Once T-cells are collected from the patient, they are genetically engineered to express...
Approved
Matched Description: … It is marketed under the brand name Yescarta and is used to treat large B-cell lymphomas and follicular ... kill cancer cells, and are infused back into the patient. ... collected from the patient, they are genetically engineered to express anti-CD19 CARs that recognize and …
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …

Vespula squamosa venom protein

Vespula squamosa venom protein is an extract of Vespula squamosa venom. Vespula squamosa venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …

Sotatercept

Sotatercept is an activin signalling inhibitor. It is a homodimeric recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA (ActRIIA) linked to the human IgG1 Fc domain. On March 26, 2024, sotatercept was approved by the FDA for the treatment of pulmonary arterial hypertension...
Approved
Investigational
Matched Description: … [L50361] Sotatercept works to resolve the imbalance in activin–growth differentiation factor and BMP …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Deucravacitinib

Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target.[A246938, A246943] This selectivity towards TYK2 may...
Approved
Investigational
Matched Description: … triglyceride levels and liver and kidney dysfunction. ... [L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines ... nonselective JAK inhibitors are associated with a range of adverse effects such as altered cholesterol and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Efbemalenograstim alfa

Efbemalenograstim alfa is a long-acting recombinant fusion protein of granulocyte-colony stimulating factor (G-CSF) due to the addition of the Fc portion of human IgG2, allowing for once-per-cycle administration.[L48852,A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and eventually neutrophils, the administration of recombinant G-CSF like efbemalenograstim...
Approved
Matched Description: … GC-627-05 in the US and Europe respectively. ... thus reducing the severity and duration of neutropenia. ... A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Protamine sulfate

Since it's earliest discovery in salmon rine sperm heads in the late 1800's to its formal introduction via US FDA approval in 1939, protamine sulfate has occupied an important therapeutic niche as perhaps the only viable option for reversing the anticoagulant effect of heparin use for over 77 years [A174778,...
Approved
Matched Description: … kidney tissue damage, and anaphylactic reaction, amongst others [A174778, L5371]. ... reversal predominantly via the formation of an inactive complex between the anionic nature of heparin and ... potential range in reversing all parenteral anticoagulants are sometimes considered high and limited …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Displaying drugs 2326 - 2350 of 15090 in total